A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  White, Michael T ^a   Bejon, Philip ^b,c   Olotu, Ally ^b   Griffin, Jamie T ^a   Bojang, Kalifa ^d   Lusingu, John ^e   Salim, Nahya ^f   Abdulla, Salim ^f   Otsyula, Nekoye ^g   Agnandji, Selidji T ^h,i   Lell, Bertrand ^h,i   Asante, Kwaku P ^j   Owusu Agyei, Seth ^j   Mahama, Emmanuel ^j   Agbenyega, Tsiri ^k   Ansong, Daniel ^k   Sacarlal, Jahit ^l,m   Aponte, John J ^l,n   Ghani, Azra C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^f IFAKARA HEALTH INSTITUTE   (Tanzania)

^g US Army Medical Research Unit Kenya   (Kenya)

^h ALBERT SCHWEITZER HOSPITAL   (Gabon)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j KINTAMPO HEALTH RESEARCH CENTRE   (Ghana)

^k School of Medical Sciences   (Ghana)

^l Manhiça Health Research Center   (Mozambique)

^m EDUARDO MONDLANE UNIVERSITY   (Mozambique)

ⁿ CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

more..

Author keywords

Antibody; Circumsporozoite protein; Clinical immunity; Malaria; Mathematical model; Phase 2 clinical trials; RTS,S; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PARASITE ANTIBODY; RTS,S MALARIA VACCINE; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOGENICITY; INFANT; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MULTICENTER STUDY; PARASITE PREVALENCE; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; AFRICA SOUTH OF THE SAHARA; BAYES THEOREM; FEMALE; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIBODIES, PROTOZOAN; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PROTOZOAN PROTEINS; TREATMENT OUTCOME; VACCINATION;

EID: 84905922963     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-014-0117-2     Document Type: Article

References (40)

1. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmueller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875. 22007715.
2. Mian-McCarthy S, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmueller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
3. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nat Med 2013, 19:168-178. 23389617.
4. Bejon P, White MT, Olotu A, Bojang K, Lusingu J, Salim N, Otsyula N, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC. Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013, 13:319-327. 23454164.
5. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of P. falciparum malaria disease in sub-Saharan Africa. Nat Commun 2014, 5:3136. 24518518.
6. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois M, Demoitie´ MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532. 19064627.
7. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie´ MA, Dubovsky F, Mene´ndez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420. 15488216.
8. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Mo¨ller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, et al. Safety and efficacy of the RTS, S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:741-749. 21782519.
9. Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois MC, Demoitie MA, Carter T, Villafana T, Ballou WR, Cohen J, Kremsner PG. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS, S malaria vaccine candidates in children in Gabon. Plos One 2009, 4:e7611. 19859560.
10. Owusu-Agyei S, Ansong D, Asante K, Owusu SK, Owusu R, Brobby NAW, Dosoo D, Akoto AO, Osei-Kwakye K, Adjei EA, Boahen KO, Sylverken J, Adjei G, Sambian D, Apanga S, Kayan K, Vekemans J, Ofori-Anyinam O, Leach A, Lievens M, Demoitie MA, Dubois MC, Cohen J, Ballou WR, Savarese B, Chandramohan D, Gyapong JO, Milligan P, Antwi S, Agbenyega T, et al. Randomized controlled trial of RTS, S/AS02(D) and RTS, S/AS01(E) malaria candidate vaccines given according to different schedules in Ghanaian children. Plos One 2009, 4:7302.
11. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitie´ MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M. Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med 2008, 359:2533-2544. 19064623.
12. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS, S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934. 11747915.
13. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, Ofori-Anyinam O, Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Leach A, Cohen J, Ballou WR, Heppner DG. Evaluation of RTS, S/AS02A and RTS, S/AS01B in adults in a high malaria transmission area. PLoS One 2009, 4:e6465. 19649245.
14. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, Lievens M, Bassat Q, Lafuente S, Macete E, Vekemans J, Guinovart C, Sigau´que B, Sillman M, Milman J, Dubois MC, Demoitie´ MA, Thonnard J, Mene´ndez C, Ballou WR, Cohen J, Alonso PL. Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009, 200:329-336. 19569964.
15. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, Bejon P. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120. 23514288.
16. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitie´ MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370:1543-1551. 17949807.
17. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011, 10:378. 22185615.
18. Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 2011, 10:223. 21816032.
19. Dalby T, Petersen JW, Harboe ZB, Krogfelt KA. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 2010, 59:1029-1036. 20508003.
20. White M, Griffin JT, Akpogheneta OJ, Conway DJ, Koram KA, Riley E, Ghani AC: Dynamics of the antibody response toPlasmodium falciparuminfection in African children.J Infect Dis. in press..
21. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC. The relationship between RTS, S vaccine-induced antibodies, CD4(+) T cell responses and protection against plasmodium falciparum infection. Plos One 2013, 8:e61395. 23613845.
22. White MT, Griffin JT, Riley EM, Drakeley CJ, Moorman AM, Sumba PO, Kazura JW, Ghani AC, John CC. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc Biol Sci 2011, 278:1298-1305. 20943696.
23. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois M-C, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011, 11:102-109. 21237715.
24. Sharp BL, Kleinschmidt I, Streat E, Maharaj R, Barnes KI, Durrheim DN, Ridl FC, Morris N, Seocharan I, Kunene S, LA Grange JJ, Mthembu JD, Maartens F, Martin CL, Barreto A. Seven years of regional malaria control collaboration - Mozambique, South Africa, and Swaziland. Am J Trop Med Hyg 2007, 76:42-47. 17255227.
25. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008, 9:725-732. 18563083.
26. Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine 2008, 26:6064-6067. 18812198.
27. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso PR, Siber G, Kohberger R, Madore DV, Malinowski FJ, Kimura A, Le C, Landaw I, Aguilar J, Hansen J. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18:757-763. 10493334.
28. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996, 348:1688-1692. 8973430.
29. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007, 196:1304-1312. 17922394.
30. Prentice RL. Surrogate endpoints in clinical-trials - definition and operational criteria. Stat Med 1989, 8:431-440. 2727467.
31. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, Remarque EJ, Roeffen W, Jansens A, Zimmerman D, Vos M, van Schaijk BC, Wiersma J, van der Ven AJ, de Mast Q, van Lieshout L, Verweij JJ, Hermsen CC, Scholzen A, Sauerwein RW. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 2013, 110:7862-7867. 23599283.
32. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365. 23929949.
33. Foquet L, Hermsen CC, van Gemert GJ, Van Braeckel E, Weening KE, Sauerwein R, Meuleman P, Leroux-Roels G. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest 2014, 124:140-144. 24292709.
34. Moorthy V, Ballou WR. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. Malar J 2009, 8:312. 20042088.
35. Olotu A, Moris PJ, Mwacharo J, Vekemans J, Kimani D, Janssens MH, Kai O, Jongert E, Lievens M, Leach A, Villafana T, Savarese B, Marsh K, Cohen J, Bejon P. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P. falciparum clinical malaria. PLoS One 2011, 6:e25786. 21998698.
36. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346. 19569965.
37. Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P. Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS, S malaria vaccine: analysis of pooled phase II clinical trial data. BMC Med 2013, 11:184. 23962071.
38. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG. Immunoglobulin G subclass-specific responses against plasmodium falciparum merozoite antigens Are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009, 77:1165-1174. 19139189.
39. Duah NO, Miles DJ, Whittle HC, Conway DJ. Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol 2010, 32:125-134. 20070826.
40. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, Tanner M. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PloS Med 2012, 9:e1001157. 22272189.